

Nakhle S Saba

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8715681/nakhle-s-saba-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66

papers

1,286

citations

15

h-index

35

g-index

67

ext. papers

1,631

ext. citations

5.1

avg. IF

4

L-index

#	Paper	IF	Citations
66	CRISPR-based Assay Reveals SARS-CoV-2 RNA Dynamic Changes and Redistribution Patterns in Non-Human Primate Model.. <i>Emerging Microbes and Infections</i> , 2022 , 1-24	18.9	
65	A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 1418-1418	2.2	
64	CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage. <i>Leukemia and Lymphoma</i> , 2021 , 1-7	1.9	1
63	Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study. <i>Targeted Oncology</i> , 2021 , 16, 761-771	5	0
62	Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	8
61	Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC). <i>Leukemia and Lymphoma</i> , 2021 , 62, 2539-2542	1.9	1
60	Liposome-mediated detection of SARS-CoV-2 RNA-positive extracellular vesicles in plasma. <i>Nature Nanotechnology</i> , 2021 , 16, 1039-1044	28.7	16
59	High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies. <i>Leukemia Research</i> , 2021 , 106, 106582	2.7	1
58	Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: A report of 17 patients. <i>Transfusion Medicine</i> , 2021 , 31, 217-220	1.3	11
57	A smartphone-read ultrasensitive and quantitative saliva test for COVID-19. <i>Science Advances</i> , 2021 , 7,	14.3	76
56	The prognostic implications of tetraploidy/near-Tetraploidy in acute myeloid leukemia: a case series and systematic review of the literature. <i>Leukemia and Lymphoma</i> , 2021 , 62, 203-210	1.9	0
55	Successful treatment of "accelerated" chronic lymphocytic leukemia with single agent ibrutinib: A report of two cases. <i>Leukemia Research Reports</i> , 2021 , 15, 100247	0.6	1
54	Systemic vs. intrathecal central nervous system prophylaxis in primary adrenal/renal diffuse large b-cell LYMPHOMA: A multi-institution retrospective analysis and systematic review. <i>Leukemia Research Reports</i> , 2021 , 16, 100263	0.6	
53	Reinfection versus failure of viral clearance in a COVID-19 patient with hematologic malignancy. <i>Leukemia Research</i> , 2021 , 101, 106514	2.7	2
52	Treatment of myeloid sarcoma without bone marrow involvement with gemtuzumab ozogamicin-containing regimen. <i>Leukemia Research</i> , 2021 , 106, 106583	2.7	1
51	Cancer and COVID-19: analysis of patient outcomes. <i>Future Oncology</i> , 2021 , 17, 3499-3510	3.6	2
50	The utility of hyperbaric oxygen therapy in post-transplant cyclophosphamide-induced hemorrhagic cystitis: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2021 , 15, 1	1.2	8

49	COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2354-2356	4.4	20
48	COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality. <i>Blood</i> , 2020 , 136, 6-7	2.2	1
47	Post-Marketing Observational Study to Assess the Incidence of Infusion-Related Reactions in Adult Patients with Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes Who Were Treated with CPX-351. <i>Blood</i> , 2020 , 136, 19-19	2.2	
46	COVID-19 Convalescent Plasma Decreased Oxygen Requirement and Hospital Stay in COVID-19 Hospitalized Patients Including Those with Hematological Malignancies: A Report of 16 Patients. <i>Blood</i> , 2020 , 136, 40-41	2.2	1
45	Primary Dural Diffuse Large B-cell Lymphoma: A Comprehensive Review of Survival and Treatment Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e105-e112	2	2
44	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019 , 25, 5143-5155	12.9	6
43	The Paracaspase MALT1 Acts Independently of Pre-B-Cell Receptor Signaling As a Key Factor in Leukemic Cell Survival in Precursor B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019 , 134, 1288-1288	2.2	
42	Central Nervous System Prophylaxis Is Required and Associated with a Prolonged Overall Survival in Both Early and Advanced-Stage Primary Adrenal/Renal Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 2908-2908	2.2	
41	Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. <i>Blood</i> , 2018 , 131, 2357-2366	2.2	120
40	A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. <i>Blood</i> , 2018 , 132, 521-532	2.2	56
39	Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma. <i>Blood</i> , 2018 , 132, 147-147	2.2	10
38	Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. <i>Leukemia</i> , 2017 , 31, 1340-1347	10.7	64
37	Long-term follow-up of patients with multiple myeloma treated with total body irradiation-Melphalan conditioning. <i>European Journal of Haematology</i> , 2017 , 99, 56-59	3.8	1
36	A centrocyte blood count of a quarter million. <i>American Journal of Hematology</i> , 2017 , 92, 972-973	7.1	0
35	MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2017 , 77, 7038-7048	10.1	33
34	Pathogenic role of B-cell receptor signaling and canonical NF- κ B activation in mantle cell lymphoma. <i>Blood</i> , 2016 , 128, 82-92	2.2	92
33	Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia. <i>JAMA Dermatology</i> , 2016 , 152, 698-701	5.1	38
32	A Systemic Review of CD5-Negative Mantle Cell Lymphoma Identifies Potential Clinical and Biological Implications. <i>Blood</i> , 2016 , 128, 3048-3048	2.2	3

31	Targeting MALT1 with the Small Molecule Inhibitor MI2 Induces a Caspase-Dependent Apoptosis and Inhibits the NF- κ B Pathway in Chronic Lymphocytic Leukemia Primary Cells. <i>Blood</i> , 2016 , 128, 1597-1597	2.2	3
30	Long-Term Outcomes of Autologous Hematopoietic Cell Transplantation Using Melphalan and Total Body Irradiation Conditioning in Multiple Myeloma. <i>Blood</i> , 2016 , 128, 4644-4644	2.2	
29	Reduction in Cell Viability and in Homeobox Protein Levels Following in Vitro Exposure to Etoposide in Acute Myeloid Leukemia. <i>Nutrition and Cancer</i> , 2016 , 68, 530-4	2.8	0
28	Quantitative assessment of chromosome instability induced through chemical disruption of mitotic progression. <i>Cell Cycle</i> , 2016 , 15, 1706-14	4.7	3
27	Disruption of pre-B-cell receptor signaling jams the WNT/ β -catenin pathway and induces cell death in B-cell acute lymphoblastic leukemia cell lines. <i>Leukemia Research</i> , 2015 ,	2.7	7
26	Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. <i>Haematologica</i> , 2015 , 100, 1571-8	6.6	113
25	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. <i>Lancet Oncology</i> , 2015 , 16, 169-76	21.7	289
24	Ibrutinib Responsive Micro-RNAs and Upregulation of Tumor Suppressor Targets in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 487-487	2.2	
23	Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. <i>Cancer Research</i> , 2014 , 74, 2520-32	10.1	170
22	Neutrophil numerals. <i>Blood</i> , 2014 , 123, 1635	2.2	1
21	Do mantle cell lymphomas have an Achilles heel? <i>Current Opinion in Hematology</i> , 2014 , 21, 350-7	3.3	13
20	Ongoing Activation of the BCR, NF κ B, and Proliferation Pathways in Mantle Cell Lymphoma: Direct in Vivo Evidence for the Role of the Lymph Node Microenvironment. <i>Blood</i> , 2014 , 124, 2991-2991	2.2	
19	Cancer of the Indiana Pouch: a case report and review of the literature. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, e30-4	3.3	2
18	Bortezomib in plasmablastic lymphoma: a case report and review of the literature. <i>Onkologie</i> , 2013 , 36, 287-91		35
17	Auranofin Induces a Reversible In-Vivo Stress Response That Correlates With a Transient Clinical Effect In Patients With Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013 , 122, 3819-3819	2.2	6
16	Gene Expression Profiling Reveals The Lymph Node Microenvironment As a Niche For BCR Engagement, NF κ B Pathway Activation, and Tumor Proliferation In Mantle Cell Lymphoma. <i>Blood</i> , 2013 , 122, 82-82	2.2	2
15	Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs. <i>PLoS ONE</i> , 2013 , 8, e75252	3.7	19
14	High-Resolution Genomic Methylation Analysis Using Next Generation Sequencing Identifies Loci Associated With Differential Prognosis In Mantle Cell Lymphoma Patients Treated With Bortezomib + DA-EPOCH-R. <i>Blood</i> , 2013 , 122, 3760-3760	2.2	

13	Protein kinase C-beta inhibition induces apoptosis and inhibits cell cycle progression in acquired immunodeficiency syndrome-related non-hodgkin lymphoma cells. <i>Journal of Investigative Medicine</i> , 2012 , 60, 29-38	2.9	6
12	Ibrutinib (PCI 32765) Rapidly Improves Platelet Counts in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) Patients and Has Minimal Effects On Platelet Aggregation. <i>Blood</i> , 2012 , 120, 1789-1789	2.2	9
11	Rapid Decrease in Overall Tumor Burden On Ibrutinib (PCI-32765) in CLL Despite Transient Increase in ALC Indicates a Significant Degree of Treatment Induced Cell Death.. <i>Blood</i> , 2012 , 120, 2899-2899	2.2	2
10	Enzastaurin Induces Apoptosis and Cell Cycle Arrest in B-Cell Acute Lymphoblastic Leukemia Cell Lines Through AKT Pathway Inhibition and E-Catenin Accumulation. <i>Blood</i> , 2012 , 120, 1350-1350	2.2	
9	The Gold Compound Auranofin Induces Oxidative Stress and Apoptosis in Primary CLL Cells Independent of Classic Prognostic Markers and the Protective Effect of the Tissue Microenvironment. <i>Blood</i> , 2012 , 120, 865-865	2.2	
8	Direct in Vivo Evidence of Increased Chronic Lymphocytic Leukemia Cell Proliferation in Lymph Nodes Compared to Bone Marrow and Peripheral Blood. <i>Blood</i> , 2012 , 120, 184-184	2.2	
7	Apoptotic induction in B-cell acute lymphoblastic leukemia cell lines treated with a protein kinase C inhibitor. <i>Leukemia and Lymphoma</i> , 2011 , 52, 877-86	1.9	7
6	Images in clinical medicine. Chemotherapy-induced hyperpigmentation of the tongue. <i>New England Journal of Medicine</i> , 2011 , 365, e20	59.2	12
5	Adjuvant high-dose interferon- α for resected melanoma in a patient with HIV infection. <i>Oncologist</i> , 2010 , 15, 695-8	5.7	0
4	Selective Protein Kinase C Inhibition Induces Apoptosis and Arrests Cell Cycle in AIDS-Related Non-Hodgkin Lymphoma Cell Lines.. <i>Blood</i> , 2009 , 114, 4807-4807	2.2	
3	Effect of Protein Kinase C Specific Inhibition On Acute Lymphoblastic Leukemia Cell Lines.. <i>Blood</i> , 2009 , 114, 4817-4817	2.2	
2	Adalimumab-induced acute myelogenous leukemia. <i>Southern Medical Journal</i> , 2008 , 101, 1261-2	0.6	15
1	Vitamin E Isoforms Inhibit Cell Proliferation and Downregulate Homeobox Protein Expression in the Leukemic KG-1 Cells.. <i>Blood</i> , 2007 , 110, 4304-4304	2.2	